- Legend CEO Ying Huang resigns; Carvykti chief named interim leaderLegend Biotech, the developer of the blockbuster cancer therapy Carvykti, is in the market for a new CEO. Ying Huang stepped down Friday after serving as CEO since November 2020, Legend announced…Endpoints · 21h ago↗ source
- STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and moreAn FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more availableSTAT · 21h ago↗ source
- STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drugAhead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.